Compare Bio-Rad Laboratories, Inc. Class A Common Stock (BIO) vs iShares 0 3 Month Treasury Bond ETF (SGOV) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Bio-Rad Laboratories, Inc. Class A Common Stock vs iShares 0 3 Month Treasury Bond ETF — how do they compare? Bio-Rad Laboratories, Inc. Class A Common Stock trades at $296.58 (market cap $8.04B), while iShares 0 3 Month Treasury Bond ETF trades at $100.54. Which is the better fit depends on your goals.
| BIO | SGOV | |
|---|---|---|
Market Cap | $8.04B | — |
Sector | Health | Fixed Income |
52-Week High | $339.75 | $100.74 |
52-Week Low | $241.71 | $100.28 |
Enterprise Value | $7.85B | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
BIO trades at $297.58, up 0.5% on the day, with a bullish technical signal from moving averages and a consensus analyst price target of $305. The stock shows strong profitability with a 51.87% gross margin and positive net income of $760M in 2025, though recent quarters have seen EPS misses. Cash flow from operations remains robust at $532M, supporting financial stability.
Outlook is cautiously optimistic with analyst support, but risks include earnings volatility and high P/E valuation. The company's return to profitability and solid balance sheet provide a foundation for growth, though investors should monitor execution against future earnings expectations and competitive pressures in the biotech sector.
SGOV, the iShares 0-3 Month Treasury Bond ETF, trades at $100.52, up 0.02% on the day. The technical outlook is bearish with moving averages signaling caution, while oscillators remain neutral. Recent news highlights strong inflows into cash ETFs amid market volatility and Federal Reserve uncertainty. The fund offers a low-risk haven with a 0.09% expense ratio and yields around 3.54–3.65%, attracting income-focused investors.
The outlook for SGOV is stable, providing a secure parking spot for cash with minimal interest rate risk due to its short duration. Investment opportunity lies in capital preservation and competitive yield versus savings accounts. Primary risks include potential Fed rate cuts reducing yields and high investor concentration in cash-like assets if equity markets rally. The fund suits conservative portfolios seeking liquidity and safety.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Bio-Rad Laboratories, Inc. Class A Common Stock
Bio-Rad Laboratories, headquartered in Hercules, California, develops, manufactures, and markets products and solutions for the clinical diagnostics and life sciences markets. In diagnostics (53% of sales), Bio-Rad manufactures, sells, and supports test systems and specialized quality controls for clinical laboratories. In life sciences (47% of sales), the firm develops and manufactures a range of instruments and reagents used in research, biopharmaceutical production, and food testing. The company is geographically diverse, with major markets in the Americas (42% of 2021 sales), Europe and Africa (33%), and Asia-Pacific (25%). Bio-Rad owns 37% of Sartorius AG, a laboratory and biopharmaceutical supplier.
Read more on BIO →About iShares 0 3 Month Treasury Bond ETF
SGOV provides exposure to ultra-short-term U.S. Treasury bills with maturities of three months or less. It functions as a high-liquidity cash alternative, seeking to provide current income while maintaining a stable net asset value and minimal interest rate risk.
Read more on SGOV →
